



## Curriculum Vitae

*\*Please provide your head-shot photo in high resolution along with this CV form.*

Name: Angelo De Marzo

Affiliation: Professor, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University

Short Biography (maximum of 400 words):

Dr. De Marzo obtained his M.D. and Ph.D. degrees from the University of Colorado Health Sciences Center. He completed a residency and at Johns Hopkins, where he is currently Professor of Pathology, Urology and Oncology at The Johns Hopkins University School of Medicine, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and The Brady Urological Research Institute. Dr. De Marzo served as director of the Pathology Core for the U.S. NIH/NCI funded Johns Hopkins prostate SPORE for 17 years. He has also been the site Principle Investigator for the U.S. DOD funded Prostate Cancer Biospecimen Network and the Co-PI of an NIH funded P01 grant related to the Molecular and Cellular Characterization of Screen-Detected Cancer Lesions in Cancer. Dr. De Marzo has led efforts in constructing numerous tissue microarrays and the development of an open source tissue microarray software and database system (TMAJ). He is board certified in anatomic pathology and has more than 15 years of experience in prostate and genitourinary pathology. At Johns Hopkins, he currently serves as the Associate Director of Pathology Cancer Research, in which he functions as a liaison between the pathology department and the Sidney Kimmel Comprehensive Cancer Center Hopkins to facilitate interactions between investigators from both programs to enhance translational research. Dr. De Marzo has served on the faculty for the Vail AACR/ASCO Workshop on Clinical Trials for 7 years and in 2017 at the Zeist AACR/ASCO Workshop on Clinical Trials. He has published more than 300 papers and he and colleagues described a potential new prostate cancer precursor/risk factor lesion for prostate cancer, proliferative inflammatory atrophy. His laboratory lab continues to study the role of inflammation, the MYC oncogene and the PTEN tumor suppressor in prostate cancer development and progression.

In addition, his laboratory also has a number of ongoing translational research efforts focused largely on using immunohistochemistry against PTEN and other biomarkers where such biomarkers might aid in diagnosis, prognosis, treatment stratification and disease resistance monitoring. Over the last few years, his laboratory has also been performing extensive studies using multiplex immune fluorescence staining for



# ATC 2017

*Antibody Therapeutics Conference*

inflammatory cells as well as RNA in situ hybridization for a number of different RNA targets.

## Speech Summary at ATC 2017

|               |  |
|---------------|--|
| Speech Title: | Tissue-based biomarker measurements in immune-oncology: where are we at and where we are heading |
|---------------|--|

|                                |
|--------------------------------|
| Speech Summary (200-500 words) |
|--------------------------------|

The field of molecular pathology relating to immune-oncology is rapidly coming into fruition and is evolving extremely quickly. This lecture will focus on tissue-based biomarker assessments in molecular pathology as related to immune-oncology. A number of technologies will be discussed from antibody validation for IHC and multi-plex immunofluorescence assays, nano-string, RNAseq and single cell RNAseq. Material will be focused on both research and clinical application to biomarker development in oncology.